Blue Jet Healthcare Limited engages in the manufacturing and sale of pharmaceutical intermediates and active pharmaceutical ingredients (APIs) for use in pharmaceutical and healthcare products. It provides contrast media intermediates; niche pharmaceutical intermediates and APIs; and CDMO/CMO services, as well as end-to-end solutions from process development and commercialization of NCEs, advance intermediates, API, and building blocks. The company develops, manufactures, and markets saccharin and related salts. It has operations in India, Norway, France, the United States, Italy, Sweden, and internationally. Blue Jet Healthcare Limited was incorporated in 1968 and is headquartered in Thane, India.
| Current Price | ₹452.50 |
|---|---|
| Market Cap | ₹7,849 Cr |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Pharmaceuticals > Pharmaceutical Contract Manufacturing Services |
| P/E Ratio | 31.7 |
| Return on Equity | 19.88% |
| 52-Week Range | ₹325.00 – ₹1,027.80 |
| Beta (1Y) | 1.24 |
| Dividend Yield | 0.27% |
1. Artificial Sweetener, Contrast Media Intermediate, Pharma Intermediate, APls-100%
Blue Jet Healthcare Ltd is trading at ₹452.50, with a market capitalisation of ₹7,849 Cr.
Blue Jet Healthcare Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Pharmaceuticals > Pharmaceutical Contract Manufacturing Services).
Blue Jet Healthcare Ltd has a P/E of 31.7 and a return on equity of 19.88%.